Profile data is unavailable for this security.
About the company
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
- Revenue in USD (TTM)0.00
- Net income in USD-40.56m
- Incorporated2009
- Employees25.00
- LocationPDS Biotechnology Corp303A College Road EastPRINCETON 08540United StatesUSA
- Fax+1 (908) 790-1212
- Websitehttps://www.pdsbiotech.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VolitionRX Ltd | 1.29m | -29.87m | 73.12m | 110.00 | -- | -- | -- | 56.87 | -0.3623 | -0.3623 | 0.0155 | -0.2328 | 0.0837 | -- | 7.41 | 11,689.36 | -196.61 | -111.92 | -- | -196.20 | -- | -- | -2,348.71 | -10,793.31 | -- | -104.15 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 74.16m | 143.00 | -- | 0.3506 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| ALX Oncology Holdings Inc | 0.00 | -151.16m | 74.37m | 89.00 | -- | 0.5436 | -- | -- | -2.98 | -2.98 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -74.50 | -34.34 | -89.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0851 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Ovid Therapeutics Inc | 631.56k | -32.50m | 74.52m | 25.00 | -- | 0.9773 | -- | 117.99 | -0.4598 | -0.4598 | 0.0089 | 1.07 | 0.0056 | -- | -- | 15,789.00 | -28.55 | -20.78 | -31.34 | -23.27 | -- | -- | -5,146.15 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -32.28m | 75.27m | 16.00 | -- | 4.74 | -- | -- | -0.7113 | -0.7113 | 0.00 | 0.2468 | 0.00 | -- | -- | 0.00 | -186.64 | -111.48 | -527.32 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Bioatla Inc | 11.00m | -81.82m | 75.90m | 65.00 | -- | 3.30 | -- | 6.90 | -1.70 | -1.70 | 0.2284 | 0.4751 | 0.103 | -- | -- | 169,230.80 | -76.61 | -48.72 | -103.22 | -57.35 | -- | -- | -743.79 | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| P3 Health Partners Inc | 1.48bn | -102.69m | 76.19m | 400.00 | -- | 0.2863 | -- | 0.0516 | -0.753 | -0.753 | 11.08 | 0.744 | 1.71 | -- | 12.28 | 3,691,575.00 | -28.94 | -- | -83.29 | -- | -2.72 | 0.1781 | -16.95 | -56.93 | -- | -12.94 | 0.3358 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 76.39m | 12.00 | -- | 9.29 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -84.61m | 76.79m | 51.00 | -- | 0.954 | -- | -- | -2.99 | -2.99 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -72.99 | -- | -81.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.56m | 76.95m | 25.00 | -- | 3.50 | -- | -- | -1.17 | -1.17 | 0.00 | 0.5975 | 0.00 | -- | -- | 0.00 | -73.98 | -51.63 | -98.74 | -59.00 | -- | -- | -- | -- | -- | -19.13 | 0.5286 | -- | -- | -- | -5.11 | -- | -- | -- |
| Allakos Inc | 0.00 | -178.75m | 78.32m | 131.00 | -- | 1.08 | -- | -- | -2.03 | -2.03 | 0.00 | 0.8142 | 0.00 | -- | -- | 0.00 | -87.64 | -42.71 | -97.01 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Agenus Inc | 160.43m | -227.86m | 78.35m | 389.00 | -- | -- | -- | 0.4884 | -11.06 | -11.06 | 7.81 | -13.48 | 0.559 | -- | 259.38 | 412,408.80 | -81.56 | -55.02 | -663.00 | -115.31 | 99.61 | -- | -145.89 | -102.92 | -- | -0.7247 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| CervoMed Inc | 10.07m | -11.95m | 79.24m | 8.00 | -- | 1.74 | -- | 7.87 | -1.60 | -1.60 | 1.35 | 5.53 | 0.3305 | -- | -- | 1,258,319.00 | -39.22 | -53.67 | -43.28 | -58.89 | -- | -- | -118.68 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Chimerix Inc | 159.00k | -83.59m | 80.94m | 72.00 | -- | 0.5961 | -- | 509.07 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 81.23m | 50.00 | -- | 0.6301 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to PDS Biotechnology Corp's reporting currency: US Dollar USD
9.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.51m | 4.10% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 482.03k | 1.31% |
| Geode Capital Management LLCas of 30 Sep 2024 | 415.11k | 1.13% |
| Inspirion Wealth Advisors LLCas of 30 Sep 2024 | 344.39k | 0.94% |
| Millennium Management LLCas of 30 Sep 2024 | 234.21k | 0.64% |
| Susquehanna Financial Group LLLPas of 30 Sep 2024 | 134.26k | 0.37% |
| William Blair Investment Management LLCas of 30 Sep 2024 | 121.74k | 0.33% |
| Citadel Securities LLCas of 30 Sep 2024 | 114.98k | 0.31% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 111.83k | 0.30% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 92.79k | 0.25% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
